TFF1 Antikörper (AA 57-84)

Produktnummer ABIN3025059

Der Maus Monoklonal Anti-TFF1-Antikörper wurde für IF, FACS und IHC (p) validiert. Er ist geeignet, TFF1 in Proben von Human und Cynomolgus zu detektieren.

Kurzübersicht für TFF1 Antikörper (AA 57-84) (ABIN3025059)

Target: TFF1 (Trefoil Factor 1 (TFF1))

Reaktivität: Human, Cynomolgus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TFF1 Antikörper ist unkonjugiert

Applikation: Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: SPM313

Produktdetails anti-TFF1 Antikörper

Bindungsspezifität: AA 57-84

Produktmerkmale: It recognizes a polypeptide of 6.5 kDa, identified as pS2 estrogen-regulated protein. Its epitope is localized between aa57-84 of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

Aufreinigung: Protein G affinity chromatography

Immunogen: Amino acids CFDDTVRGVPWCFYPNTIDVPPEEECEF (aa57-84) from the human protein were used as the immunogen for the Estrogen Inducible Protein pS2 antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Estrogen Inducible Protein pS2 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the Estrogen Inducible Protein pS2 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu TFF1

Target: TFF1 (Trefoil Factor 1 (TFF1))

Andere Bezeichnung: Estrogen Inducible Protein pS2

Hintergrund: It recognizes a polypeptide of 6.5  kDa, identified as pS2 estrogen-regulated protein. Its epitope is localized between aa57-84 of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

Pathways: EGFR Signaling Pathway